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ABSTRACT
Increased resistance to ﬂuconazole has been reported in oral, oesophageal and urinary Candida isolates,
but this has not been observed commonly in genital tract isolates. The rate of isolation of Candida spp.
and their susceptibility to amphotericin B, ﬂucytosine and azoles were determined in a number of
clinical practices in the city of Ghent, Belgium. Patients with symptomatic vulvovaginal candidiasis
(VVC) were treated with ﬂuconazole, and the mycological and clinical outcomes were evaluated.
Isolates were identiﬁed as Candida albicans (78.6%), Candida guilliermondii (17.3%), Candida glabrata
(2.6%) and Candida dubliniensis (1.3%). The rates of mycological and clinical cures were 79.5% and
100%, respectively. Women with recurrent VVC were infected more frequently by non-albicans Candida
spp., but no association was found between the use of antifungal agents and the presence of non-albicans
spp. In-vitro resistance to ﬂuconazole was not detected, even among subsequent Candida isolates from
nine patients for whom mycological cure was not achieved.
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INTRODUCTION
Vulvovaginal candidiasis (VVC) is a common
mucosal infection among immunocompetent,
healthy women, and is caused by members of
the genus Candida, predominantly Candida albicans
[1]. There is little evidence of a signiﬁcant increase
in the prevalence of fungal vaginitis caused by
non-albicans Candida spp. [2,3]. In most VVC
patients, oral treatment with antifungal agents,
e.g., ﬂuconazole, quickly relieves symptoms.
Systemic antimycotic therapy could lead to the
selection of non-albicans Candida strains [4], which
are reportedly less sensitive to the antifungal
agents used most frequently [5,6]. While the
susceptibility of Candida blood isolates has
remained essentially unchanged during recent
years [7,8], increasing resistance to ﬂuconazole
has been reported in oral, oesophageal and
urinary Candida isolates [9–12]. To evaluate the
effect of the widespread use of antifungal agents
on the occurrence of VVC, it is important to
monitor the rate of isolation of vaginal Candida
spp. and to study their susceptibilities to anti-
mycotic agents.
In the present study, patients with sympto-
matic VVC from Ghent, Belgium, were treated
with ﬂuconazole, and their mycological and
clinical outcomes were evaluated. The suscepti-
bility of isolates was assessed using NCCLS,
EUCAST and Etest methods in order to evaluate
the correlation between in-vitro susceptibility
results and outcome, and to ascertain the degree
of antifungal resistance among vaginal Candida
isolates.
MATERIALS AND METHODS
Patients
The study was conducted between September 2002 and
September 2003, and included 77 women with a clinical
diagnosis of VVC who visited outpatient clinics of the
Corresponding author and reprint requests: H. J. Nelis,
Harelbekestraat 72, 9000 Gent, Belgium
E-mail: Hans.Nelis@UGent.be
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Departments of Gynaecology of four hospitals in Ghent, the
Gynaecological Centre of Ghent, and a private physician’s
practice in Ghent. The study was approved by the Ethical
Committee of Ghent University Hospital. Only women with
clinical signs and symptoms of vaginitis (i.e., presence of
vulvar pruritis and vaginal discharge, itching, burning pain or
erythema) were included in the study. These patients were
examined on two occasions. At the ﬁrst visit, a vaginal swab
was obtained and each patient was prescribed ﬂuconazole
150 mg daily for 1 week. High-risk patients (e.g., those being
treated with antibiotics, corticosteroids, immunosuppressive
drugs or cytotoxic chemotherapeutic agents, diabetic patients,
and patients with recurrent Candida infection) received 200 mg
daily. Lactating and pregnant women, or women suspected of
being pregnant, were excluded from the study. After 1 week,
patients were assessed for clinical cure, deﬁned as the
resolution of signs and symptoms after treatment, and a
second swab was taken. A mycological cure was recorded
when the ﬁrst swab was culture-positive and the second swab
was culture-negative. Each physician completed a standard-
ised questionnaire for each patient to determine the history of
vulvovaginitis, use of antifungal agents during current or
previous episodes of candidiasis, risk-factors (pregnancy,
diabetes, immunosuppression, use of contraceptives, cortico-
steroids or antibiotics), symptoms and cure. None of the
women in this study was diabetic or receiving immunosup-
pressive drugs.
Vaginal samples and identiﬁcation methods
A sample of the lateral vaginal wall was taken using a sterile
plain cotton-tipped swab. The swabs were placed in a transport
gel and processed in the laboratory within 24 h. Each swab was
extracted in 10 mL of buffered peptone by vortex mixing, and
the extracts were then ﬁltered through a 47-mm diameter,
0.45-lm pore size nylon membrane ﬁlter (Nylaﬂo; Gelman
Sciences, Ann Arbor, MI, USA). The ﬁlters were then incubated
on CHROMagar Candida (CHROMagar Co., Paris, France) for
48 h at 37C. Phenotypic conﬁrmatory tests included germ tube
formation, API 20C AUX (bioMe´rieux Vitek, Durham, NC,
USA), morphology on corn-meal agar containing Tween-80
0.5% v ⁄v, latex agglutination (Krusei-Color; Fumouze, Levall-
ois Perret, France), growth at 45C on Emmons Modiﬁed
Sabouraud dextrose agar, and trehalose assimilation.
The identity of all strains was also conﬁrmed genotypically
by PCR combined with an enzyme immunoassay, as described
by Elie et al. [13]. Molecular identiﬁcation of Candida guillier-
mondii was performed at the Centraal bureau voor Schimmel-
cultures (Utrecht, The Netherlands). DNA was isolated as
described by O’Donnell et al. [14]. The internal spacer (ITS)
region and D1 ⁄D2 domains were ampliﬁed using primers V9
(5¢-TGCGTTGATTACGTCCCTGC) and RLR3R (5¢-GGTCCGT-
GTTTCAAGAC) in 50-lL reaction volumes containing
150 nmol MgCl2, 10 nmol each dNTP, 0.05 nmol each primer,
1 U of DNA polymerase and 1 lL of isolated genomic DNA.
PCR conditions comprised 5 min at 94C, followed by 35 cycles
of 45 s at 94C, 30 s at 52C and 2 min at 72C, and a ﬁnal
elongation step for 6 min at 72C. Amplicons were puriﬁed
using a GFX PCR DNA puriﬁcation kit (Amersham Pharmacia
Biotech, Roosendaal, The Netherlands). PCR products
(10–40 ng) were used in cycle sequencing reactions in a total
volume of 10 lL, containing 1 lL of 5· sequencing buffer, 2 lL
of BigDye terminator RRmix (PE Biosystems, Nieuwerkerk aan
den IJsel, The Netherlands) and 400 nM sequencing primer.
The primers used for the ITS1, 5.8S rDNA and ITS2 domains
were ITS1 (5¢-TCCGTAGGTGAACCTGCGG) and ITS4 (5¢-TC-
CTCCGCTTATTGATATGC); the primers used for the LSU
rDNA region were NL1 (5¢-GCATATCAATAAGCGGAGGA-
AAAG) and RLR3R (5¢-GGTCCGTGTTTCAAGAC). Puriﬁca-
tion of these amplicons was performed using the MultiScreen
Filtration System (Millipore, Etten-Leur, The Netherlands) in
combination with Sephadex G-50 Super ﬁne (Amersham Phar-
macia Biotech). Sequencing was performed on an ABI 3700
capillary sequencer (PE Biosystems), with analysis by the Laser-
gene software package (DNASTAR Inc., Madison, WI, USA).
The identity of Candida dubliniensis isolates was also
conﬁrmed at the Centro National de Microbiologı´a (Majadah-
onda, Spain) by DNA sequencing of ITS regions of rDNA.
DNA segments comprising the regions ITS1 and ITS2 were
ampliﬁed with primers ITS1 (5¢-TCCGTAGGTGAACC-
TGCGG) and ITS4 (5¢-TCCTCCGCTTATTGATATGC) [15].
Reaction mixtures contained 0.025 nmol each primer, 10 nmol
each dNTP, 5 lL of 10· PCR buffer (Applied Biosystems,
Madrid, Spain), 2.5 U of Taq DNA polymerase (Amplitaq;
Applied Biosystems) and 5 ng of DNA, in a ﬁnal volume of
50 lL. Samples were ampliﬁed in a GeneAmp PCR System
2400 (Applied Biosystems) for 2 min at 94C, followed by 35
cycles of 30 s at 94C, 45 s at 56C and 2 min at 72C, and a
ﬁnal extension for 5 min at 72C. The reaction products were
analysed in agarose 1.3% w ⁄v gels. Sequencing was per-
formed using 4 lL of BigDye Terminator Cycle Sequencing
Ready Reaction (Applied Biosystems), 1 lL of primers ITS1
and ITS4, and 5 lL of PCR product, in a ﬁnal volume of 10 lL.
Sequences were assembled and edited using the SeqMan II
and EditsEq software packages (DNAstar, Inc.). The sequences
obtained were analysed by comparison with the nucleotide
sequences of Candida reference isolates obtained from
GenBank (http://www.ncbi.nih.gov/GenBank/).
Susceptibility testing
Standard powders of amphotericin B and ﬂucytosine (Sigma
Aldrich Quimica, Madrid, Spain), ﬂuconazole and voriconaz-
ole (Pﬁzer, Madrid, Spain) and itraconazole and ketoconazole
(Janssen, Madrid, Spain) were used. MICs and endpoints were
determined with the NCCLS and EUCAST reference proce-
dures [16,17]. For amphotericin B, the endpoint with the
EUCAST method was deﬁned as the lowest drug concentra-
tion that resulted in a reduction in growth of ‡ 90% compared
with that of a drug-free control well. Etests (AB Biodisk, Solna,
Sweden) for amphotericin B, ﬂucytosine, ﬂuconazole, itracon-
azole and voriconazole were provided by Izasa (Madrid,
Spain). Susceptibility testing, reading and interpretations of
the results were performed in accordance with the manufac-
turer’s instructions. Candida parapsilosis ATCC 22019 and
Candida krusei ATCC 6258 were used as quality control strains
in each set of experiments.
Data analysis
Categorical data analysis of clinical and mycological data was
carried out with SPSS v. 11.0 software (SPSS Inc., Chicago, IL,
USA). Statistical analysis was performed on the patient group
with VVC or recurrent VVC (RVVC); patients with a negative
culture were not included. Patients were divided into two
groups (VVC or RVVC). The associations between the type of
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VVC and the use of antifungal agents, and the use of
contraceptives and the presence of a non-albicans Candida sp.,
were analysed by Fisher’s exact test in a two-way contingency
table. The use of antifungal agents was considered to be a
binary variable; no distinction was made between topical and
systemic use of antifungal agents. Oral or mechanical contra-
ceptives were not considered separately, and the use of
contraceptives was included in the analysis as a binary
variable. The associations between the use of antifungal agents
and the presence of a non-albicans Candida sp., and between
infection with an isolate with a ﬂuconazole MIC > 1 mg ⁄L at
the ﬁrst visit and a mycological cure, were analysed in two-
way contingency tables.
Analysis of susceptibility results included both on- and
off-scale MICs. The lower off-scale MICs were left unchanged,
and the higher off-scale MICs were converted to the next
highest concentration. The reproducibility between NCCLS,
EUCAST and Etest results was calculated by determining the
percentage of agreement between MICs. Agreement was
deﬁned as a discrepancy in MIC results of no more than two
two-fold dilutions. Susceptibility testing results obtained by
Etest were transformed to the nearest two-fold dilution, up or
down, tested by the NCCLS reference method. In addition, the
correlation between results was evaluated by using the intra-
class correlation coefﬁcient (ICC), which was expressed to
a maximum value of 1 and with a 95% CI. In order to
approximate a normal distribution, the MICs were transformed
to log2 values, with p < 0.05 considered to be statistically
signiﬁcant. The ICC is a reverse measurement of the variability
of the counting values. Apart from the agreement (concordance
between MIC values), the ICC also evaluates the correlation
between values offering statistical signiﬁcance, since it takes
into account the number of cases and the absolute value of the
counting. The ICC is a scale analysis and exhibits the highest
statistical power for reproducibility studies.
RESULTS
Patient population
On their ﬁrst visit, 77.9% (60 ⁄ 77) of the women in
the study had VVC and were culture-positive for
Candida. Nine (15.5%) of these patients were
considered to have RVVC, while, for two patients,
the type of candidiasis was not speciﬁed. After
treatment, 44 patients returned 1 week later;
among these, cultures were still positive for
20.5% (9 ⁄ 44) at the second visit, giving a mycolog-
ical cure rate of 79.5%. None of these patients
suffered from RVVC. Sixteen of the original
patients did not return within 1 week of treatment
and no swab could be taken. The symptoms were
reduced after treatment for all women with
(R)VVC, with the exception of seven patients for
whom the outcome was not speciﬁed on the
questionnaire. The use of antimycotic agents
during previous or current episodes of candi-
diasis, as well as current use of contraceptives or
antibiotics, was assessed for the 58 patients with
knownVVC type. All patientswith RVVC received
antifungal treatment during the current or previ-
ous episodes, as opposed to 34.7% (17 ⁄ 49) of
women with a non-recurrent type of VVC. Contra-
ceptives were used by 33.3% (3 ⁄ 9) and 57.1%
(26 ⁄ 49) of women with RVVC and non-recurrent
VVC, respectively. Women with RVVC used sig-
niﬁcantly more antifungal agents (Fisher’s exact
test, p < 0.05), but there was no correlation
between use of contraceptives and the frequency
of RVVC. Only three patients had received anti-
biotics, and all three were reportedly suffering
from their ﬁrst episode of VVC.
Of all women with a clinical diagnosis of VVC,
22.1% (17 ⁄ 77) did not have a positive Candida
culture at either their ﬁrst or second visit. In these
patients, the rate of clinical cure was 75% (12 ⁄ 16).
The patients whose symptoms were not relieved
received other therapies.
Species isolated
In total, 75 isolates of Candida spp. were obtained,
i.e., 66 at the ﬁrst visit (from 60 patients) and nine
at the second visit (from nine patients). At the ﬁrst
visit, the isolates were identiﬁed as C. albicans
(84.9%; 56 ⁄ 66), C. guilliermondii (10.6%; 7 ⁄ 66),
Candida glabrata (3.0%; 2 ⁄ 66) and C. dubliniensis
(1.5%; 1 ⁄ 66). Infection with non-albicans Candida
spp. occurred in 44.5% of patients with RVVC.
Thus, women with RVVC were signiﬁcantly more
likely to be infected by non-albicans Candida spp.
than those with non-recurrent VVC (Fisher’s exact
test, p < 0.05). No association was found between
the use of antifungal agents and the presence of
non-albicans Candida spp. (p < 0.05). The species
isolated at the second visit were identiﬁed as
C. guilliermondii (66.7%; 6 ⁄ 9) and C. albicans
(33.3%; 3 ⁄ 9).
Susceptibility testing results
Table 1 summarises the in-vitro susceptibilities of
the 75 Candida isolates to the six antifungal agents,
as determined with the EUCAST, NCCLS and
Etest methods. C. albicans and C. guilliermondii
differed most in susceptibility pattern among the
azoles. For C. guilliermondii, the MIC ranges were
broader and the geometric means were higher
than those for C. albicans.
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Agreement was 97% between the NCCLS and
EUCAST MICs, 93% between NCCLS and Etest
data, and 92% between EUCAST and Etest data.
The ICCs were 0.91 for NCCLS and EUCAST
MICs, 0.88 for NCCLS and Etest data, and 0.89 for
EUCAST and Etest susceptibility results. The ICC
values were statistically signiﬁcant (p < 0.05). The
lowest percentages of agreement and ICCs, i.e.,
< 80% and 0.70 (p < 0.05), respectively, were for
itraconazole MICs for non-albicans Candida spp.
When the susceptibility data for the ﬁrst visit
and post-treatment isolates were compared, no
difference was seen for ﬂuconazole. However,
microbiological cure was associated signiﬁcantly
(p < 0.01) with the isolation of C. albicans at the
ﬁrst visit. Isolates from patients without micro-
biological cure were largely C. guilliermondii, with
signiﬁcantly higher ﬂuconazole MICs than for
C. albicans (p < 0.05). Nevertheless, clinical cure
was achieved in all women suffering from VVC.
Despite the presence of strains with higher MICs
for ﬂuconazole, symptoms disappeared after ﬂuc-
onazole therapy.
DISCUSSION
Although monitoring of the azole susceptibilities
of blood and oral isolates of Candida is now
performed widely, limited information has been
available regarding the susceptibilities of Candida
spp. responsible for symptomatic vaginitis
[2,4,18–21]. In the present study, as reported
previously [3,4,19,22], C. albicans was identiﬁed
as the predominant species (84.9%) isolated from
patients with (R)VVC. Of the non-albicans Candida
spp., C. guilliermondii (10.6%) was the most
prevalent species, followed by C. glabrata (3%)
and C. dubliniensis (1.5%). The unusually high
isolation rate of C. guilliermondii in the present
study was similar to that reported by Mendoza
et al. [23], but contrasts with the ﬁndings of other
workers. C. guilliermondii is associated rarely with
infections in humans [24]. However, this species
has been isolated from the human gastrointestinal
and genitourinary tracts [25], and may be
involved in cutaneous and subcutaneous infec-
tions [26]. It can cause fatal fungaemia [27], but
has been reported only occasionally as a vaginal
pathogen [21,24,28,29]. Remarkably, in the pre-
sent study, all isolates originated from one
practice, implying a pseudo-outbreak caused
by cross-contamination. A pseudo-outbreak of
C. guilliermondii fungaemia, resulting from conta-
minated heparin vials, was reported by Yagupsky
et al. [24]. However, samples from the gynaecolo-
gical practice concerned did not yield C. guillier-
mondii, and the C. guilliermondii-positive samples
were not clustered in time.
Table 1. Antifungal susceptibilities of 75 isolates of Candida spp., as determined by three methods
Antifungal agent Method
MIC (mg ⁄L) for each species (no of isolates)
C. albicans (n = 59) C. dubliniensis (n = 1) C. glabrata (n = 2) C. guilliermondii (n = 13)
Range
Geometric
mean Range
Geometric
mean Range
Geometric
mean Range
Geometric
mean
Amphotericin B NCCLS 0.03–0.5 0.118 0.03–0.03 0.03 0.12–0.25 0.173 0.12–0.25 0.189
EUCAST 0.03–0.25 0.125 0.12–0.12 0.12 0.25–0.25 0.25 0.03–0.25 0.143
Etest 24 h 0.023–0.26 0.098 0.032–0.032 0.032 0.12–0.25 0.173 0.016–0.19 0.077
Etest 48 h 0.012–0.5 0.162 0.094–0.094 0.094 0.25–0.38 0.308 0.094–0.38 0.199
Flucytosine NCCLS 0.12–64 0.166 0.12–0.12 0.12 0.12–0.12 0.12 0.12–0.25 0.150
EUCAST 0.12–64 0.222 0.12–0.12 0.12 0.25–0.25 0.173 0.03–0.25 0.134
Etest 24 h 0.016–32 0.113 0.016–0.016 0.016 0.023–0.032 0.027 0.012–0.12 0.050
Etest 48 h 0.032–32 0.207 0.023–0.023 0.023 0.047–0.094 0.066 0.12–0.38 0.214
Fluconazole NCCLS 0.06–2 0.138 0.12–0.12 0.12 4–8 5.657 2–4 3.232
EUCAST 0.06–64 0.199 0.25–0.25 0.25 2–4 2.828 2–8 4.450
Etest 24 h 0.064–1 0.218 0.12–0.12 0.12 1.5–4 2.449 1–4 1.888
Etest 48 h 0.094–0.75 0.231 0.12–0.12 0.12 2–12 4.899 1.5–6 2.881
Itraconazole NCCLS 0.015–0.015 0.015 0.015–0.015 0.015 0.015–0.25 0.061 0.06–0.5 0.189
EUCAST 0.015–8 0.020 0.015–0.015 0.015 0.25–0.5 0.354 0.12–0.5 0.277
Etest 24 h 0.004–0.38 0.021 0.003–0.003 0.003 0.25–1.5 0.612 0.25–1 0.478
Etest 48 h 0.004–0.25 0.031 0.003–0.003 0.003 1–1 1 0.5–2 1.051
Voriconazole NCCLS 0.015–0.015 0.015 0.015–0.015 0.015 0.06–0.25 0.12 0.06–0.12 0.070
EUCAST 0.015–8 0.0167 0.015–0.015 0.015 0.06–0.25 0.122 0.06–0.25 0.083
Etest 24 h 0.003–0.047 0.0065 0.008–0.008 0.008 0.032–0.25 0.089 0.0032–0.064 0.030
Etest 48 h 0.003–0.094 0.006 0.004–0.004 0.004 0.047–0.5 0.153 0.032–0.12 0.057
Ketoconazolea NCCLS 0.015–0.03 0.015 0.015–0.015 0.015 0.06–0.25 0.122 0.03–0.25 0.063
EUCAST 0.015–8 0.016 0.015–0.015 0.015 0.06–0.25 0.122 0.06–0.25 0.087
aEtest not performed.
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The type of VVC correlated with the presence
of non-albicans Candida spp. Women with RVVC
were signiﬁcantly more likely to be infected by
non-albicans Candida spp. than were women with
non-recurrent VVC. Similarly, Spinillo et al. [3]
concluded that RVVC was an additional risk-
factor for vaginitis caused by non-albicans Candida
spp. As expected, women with RVVC used
signiﬁcantly more antifungal agents, which could
lead to the selection of non-albicans Candida strains
[4]; alternatively, the presence of an intrinsically
less susceptible non-albicans Candida strain could
account for RVVC. Because of the low number of
cases, an association between the use of antifun-
gal agents and the presence of non-albicans Can-
dida spp., corrected for the type of VVC, could not
be determined.
There was no correlation between use of
contraceptives and the type of VVC. Oral contra-
ceptives have been suspected of contributing to
RVVC, but epidemiological data are conﬂicting
and their role in this aetiology is still controversial
[5,30]. Three patients who received antibiotics
were suffering from their ﬁrst episode of VVC.
The use of broad-spectrum antibiotics has been
suggested as a risk-factor for acute VVC [29,31].
In the present study, susceptibility testing of 75
vaginal Candida isolates was performed with the
NCCLS, EUCAST and Etest procedures. Repro-
ducibility and correlation indices were statisti-
cally signiﬁcant (p < 0.05) and, unlike the results
of Bauters et al. [18], no discrepancy was observed
between ﬂuconazole MICs obtained with the
NCCLS and EUCAST methods. The lowest per-
centages of agreement and ICCs were obtained
for itraconazole MICs of non-albicans Candida spp.
Trailing growth, as well as non-homogeneous
itraconazole solutions, may have contributed to
this variability [32].
The overall sensitivity of vaginal C. albicans
isolates to ﬂuconazole, and the increasing resist-
ance of C. glabrata [5,6], were also conﬁrmed in the
present study. Overall, C. albicans isolates were
also sensitive to the other azoles tested, although
Sojakova et al. [4] found that vaginal isolates of
C. albicans were resistant in vitro to ﬂuconazole
and itraconazole in 14.1% and 16.6% of cases,
respectively.
To date, there have been no reports on the
in-vitro susceptibility patterns of vaginal C. guil-
liermondii isolates. With regard to C. guilliermondii
bloodstream isolates, some studies suggest that
they have moderate sensitivity to ﬂuconazole and
ketoconazole, and are susceptible to amphotericin
B and ﬂucytosine [25,33,34], while others suggest
that they are highly susceptible to ﬂuconazole,
ketoconazole, itraconazole and amphotericin B
[35,36], but resistant to ﬂucytosine [35], with all
tests having been performed according to NCCLS
methodology. In the present study, vaginal
C. guilliermondii isolates were susceptible in vitro
to amphotericin B and ﬂucytosine, but were only
moderately susceptible to azole agents, regardless
of the susceptibility testing procedure. MICs of
ﬂuconazole ranged from 1 to 8 mg ⁄L.
Correlation of in-vitro susceptibility data with
clinical outcome can be variable, depending on
the test method. Clinical resistance to ﬂucona-
zole of Candida isolates causing vulvovaginitis
was demonstrated as in-vitro resistance in about
one-third of the cases by Etest [21] or the
NCCLS method [2]. However, Costa et al. [19]
reported a positive correlation between Etest
susceptibility results and clinical outcome in
vaginal Candida infections. In the present study,
a correlation could not be established because
resistant isolates were detected only rarely
in vitro. In addition, clinical cure was observed
for all patients treated with ﬂuconazole, irres-
pective of the ﬂuconazole MIC. Isolates from
patients for whom microbiological cure was not
achieved were largely C. guilliermondii, with
ﬂuconazole MICs > 2 mg ⁄L. However, this ﬁnd-
ing could be biased because of the absence of a
representative number of C. albicans isolates
with ﬂuconazole MICs > 2 mg ⁄L, as well as
the low number of C. guilliermondii isolates with
MICs < 2 mg ⁄L.
Antifungal susceptibility tests may be an
important aid in treatment and the monitoring
of outcome. The present study shows that use of
ﬂuconazole resulted in a clinical cure for all
patients, even those with RVVC and VVC caused
by non-albicans Candida spp. or isolates with
higher in-vitro MICs for ﬂuconazole. Resistance
to ﬂuconazole was not detected in vitro before or
after treatment.
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